These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 8301568

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Decrease of D2 receptor binding but increase in D2-stimulated G-protein activation, dopamine transporter binding and behavioural sensitization in brains of mice treated with a chronic escalating dose 'binge' cocaine administration paradigm.
    Bailey A, Metaxas A, Yoo JH, McGee T, Kitchen I.
    Eur J Neurosci; 2008 Aug; 28(4):759-70. PubMed ID: 18671743
    [Abstract] [Full Text] [Related]

  • 3. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR, Kuszpit K, Sherman P.
    Synapse; 2000 Mar 15; 35(4):250-5. PubMed ID: 10657034
    [Abstract] [Full Text] [Related]

  • 4. Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity.
    Itzhak Y, Gandia C, Huang PL, Ali SF.
    J Pharmacol Exp Ther; 1998 Mar 15; 284(3):1040-7. PubMed ID: 9495865
    [Abstract] [Full Text] [Related]

  • 5. Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine.
    Woolverton WL, Wang Z.
    Eur J Pharmacol; 2004 Feb 23; 486(3):251-7. PubMed ID: 14985046
    [Abstract] [Full Text] [Related]

  • 6. Locomotor sensitization and decrease in [3H]mazindol binding to the dopamine transporter in the nucleus accumbens are delayed after chronic treatments by GBR12783 or cocaine.
    Boulay D, Duterte-Boucher D, Leroux-Nicollet I, Naudon L, Costentin J.
    J Pharmacol Exp Ther; 1996 Jul 23; 278(1):330-7. PubMed ID: 8764367
    [Abstract] [Full Text] [Related]

  • 7. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users.
    Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, Adams VI, Smialek J, Anderson WR, Shannak K, Deck J, Niznik HB, Kish SJ.
    Ann Neurol; 1996 Sep 23; 40(3):428-39. PubMed ID: 8797532
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo.
    Tolliver BK, Newman AH, Katz JL, Ho LB, Fox LM, Hsu K, Berger SP.
    J Pharmacol Exp Ther; 1999 Apr 23; 289(1):110-22. PubMed ID: 10086994
    [Abstract] [Full Text] [Related]

  • 10. In vivo labeling of cocaine binding sites on dopamine transporters with [3H]WIN 35,428.
    Scheffel U, Pögün S, Stathis M, Boja JW, Kuhar MJ.
    J Pharmacol Exp Ther; 1991 Jun 23; 257(3):954-8. PubMed ID: 2046028
    [Abstract] [Full Text] [Related]

  • 11. Prenatal cocaine exposure: decreased sensitization to cocaine and decreased striatal dopamine transporter binding in offspring.
    Byrnes JJ, Pritchard GA, Koff JM, Miller LG.
    Neuropharmacology; 1993 Jul 23; 32(7):721-3. PubMed ID: 8361584
    [Abstract] [Full Text] [Related]

  • 12. High affinity hydroxypiperidine analogues of 4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidine for the dopamine transporter: stereospecific interactions in vitro and in vivo.
    Ghorai SK, Cook C, Davis M, Venkataraman SK, George C, Beardsley PM, Reith ME, Dutta AK.
    J Med Chem; 2003 Mar 27; 46(7):1220-8. PubMed ID: 12646032
    [Abstract] [Full Text] [Related]

  • 13. Behavioral effects of novel cocaine analogs: a comparison with in vivo receptor binding potency.
    Cline EJ, Scheffel U, Boja JW, Carroll FI, Katz JL, Kuhar MJ.
    J Pharmacol Exp Ther; 1992 Mar 27; 260(3):1174-9. PubMed ID: 1545384
    [Abstract] [Full Text] [Related]

  • 14. Withdrawal of repeated intravenous infusions of cocaine persistently reduces binding to dopamine transporters in the nucleus accumbens of Lewis rats.
    Pilotte NS, Sharpe LG, Kuhar MJ.
    J Pharmacol Exp Ther; 1994 Jun 27; 269(3):963-9. PubMed ID: 7912283
    [Abstract] [Full Text] [Related]

  • 15. Modeling of the pH dependence of the binding of WIN 35,428 to the dopamine transporter in rat striatal membranes: is the bioactive form positively charged or neutral?
    Xu C, Reith ME.
    J Pharmacol Exp Ther; 1996 Sep 27; 278(3):1340-8. PubMed ID: 8819521
    [Abstract] [Full Text] [Related]

  • 16. 3'-Chloro-3 alpha-(diphenylmethoxy)tropane but not 4'-chloro-3 alpha-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile.
    Kline RH, Izenwasser S, Katz JL, Joseph DB, Bowen WD, Newman AH.
    J Med Chem; 1997 Mar 14; 40(6):851-7. PubMed ID: 9083473
    [Abstract] [Full Text] [Related]

  • 17. Effects of cocaine, nicotine, dizocipline and alcohol on mice locomotor activity: cocaine-alcohol cross-sensitization involves upregulation of striatal dopamine transporter binding sites.
    Itzhak Y, Martin JL.
    Brain Res; 1999 Feb 13; 818(2):204-11. PubMed ID: 10082805
    [Abstract] [Full Text] [Related]

  • 18. Cocaine causes a time dependent and dose dependent increase in D1 receptors and dopamine transporters.
    Wamsley JR, Alburges ME.
    Proc West Pharmacol Soc; 1993 Feb 13; 36():277-82. PubMed ID: 8378389
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.